Metastatic Colorectal Cancer (CRC)

Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
1 program
1
Fruquintinib Combined With ChemotherapyPhase 21 trial
Active Trials
NCT07042685Recruiting50Est. Dec 2029
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
BI 1701963Phase 11 trial
Active Trials
NCT04627142Terminated15Est. Jan 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
TakedaFruquintinib Combined With Chemotherapy
Boehringer IngelheimBI 1701963

Clinical Trials (2)

Total enrollment: 65 patients across 2 trials

NCT07042685TakedaFruquintinib Combined With Chemotherapy

Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer

Start: Feb 2026Est. completion: Dec 202950 patients
Phase 2Recruiting

A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutation

Start: Nov 2020Est. completion: Jan 202215 patients
Phase 1Terminated

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 65 patients
2 companies competing in this space